Eli Lilly Plans Q2 Launch of Orforglipron with $1.5B Inventory, Debuts Employer Connect Platform
Eli Lilly is preparing to launch its oral obesity drug orforglipron in the U.S. as early as Q2 with $1.5B in pre-launch inventory ready to ship within a week of FDA approval. On March 5, the company launched its Employer Connect platform to coordinate employer-based obesity care and reduce out-of-pocket costs through independent program administrators.
1. Orforglipron Launch Preparations
Eli Lilly’s finance chief confirmed the company expects FDA approval for orforglipron by Q2 and holds $1.5 billion of pre-launch inventory. The drug can be shipped to U.S. patients within about a week of approval, supporting a swift market rollout.
2. Employer Connect Platform Rollout
On March 5, Eli Lilly introduced Employer Connect to close access gaps in obesity care by linking employers with independent program administrators. The platform offers flexible benefits administration and cost-sharing solutions aimed at lowering out-of-pocket expenses for employees.